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Objective. Pulmonary arterial hypertension
(PAH) affects up to 15% of patients with connective
tissue diseases (CTDs). Previous recommendations de-
veloped as part of larger efforts in PAH did not include
detailed recommendations for patients with CTD-
associated PAH. Therefore, we sought to develop recom-
mendations for screening and early detection of CTD-
associated PAH.
Methods. We performed a systematic review of the
literature on the screening and diagnosis of PAH in
CTD. Using the RAND/University of California, Los
Angeles consensus methodology, we developed case sce-
narios followed by 2 stages of voting. First, international
experts from a variety of specialties voted anonymously
on the appropriateness of each case scenario. The
experts then met face-to-face to discuss and resolve
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discrepant votes to arrive at consensus recommenda-
tions.
Results. The key recommendation stated that all
patients with systemic sclerosis (SSc) should be
screened for PAH. In addition, patients with mixed
connective tissue disease or other CTDs with sclero-
derma features (scleroderma spectrum disorders)
should be screened for PAH. It was recommended that
screening pulmonary function tests (PFTs) with single-
breath diffusing capacity for carbon monoxide, trans-
thoracic echocardiogram, and measurement of
N-terminal pro–brain natriuretic peptide (NT-proBNP)
be performed in all patients with SSc and scleroderma
spectrum disorders. In patients with SSc and sclero-
derma spectrum disorders, transthoracic echocardio-
gram and PFTs should be performed annually. The full
screening panel (transthoracic echocardiogram, PFTs,
and measurement of NT-proBNP) should be performed
as soon as any new signs or symptoms are present.
Conclusion. We provide consensus-based,
evidence-driven recommendations for screening and
early detection of CTD-associated PAH. It is our hope
that these recommendations will lead to earlier detec-
tion of CTD-associated PAH and ultimately improve
patient outcomes.
Pulmonary arterial hypertension (PAH) affects
0.5–15% of patients with connective tissue diseases
(CTDs) and is one of the leading causes of death in
systemic sclerosis (SSc) and mixed connective tissue
disease (MCTD) (1–5). Despite increasing recognition
of PAH in CTDs, the diagnosis is often delayed, which
may lead to unfavorable outcomes in these patients
(2,6). International organizations have provided recom-
mendations for screening and detection of PAH in
CTDs, but these recommendations have been limited to
the use of transthoracic echocardiography for patients
with SSc (7–9). The established recommendations were
developed as part of larger efforts in PAH and did not
include detailed recommendations for patients with
CTD-associated PAH. Therefore, we sought to develop
recommendations for screening and early detection of
CTD-associated PAH using rigorous data-driven and
consensus-building methodology that has been used
previously to develop recommendations.
These recommendations are designed to pro-
mote screening and early detection of CTD-associated
PAH and to reflect best practice, as evaluated by a
diverse group of experts who examined the current level
of evidence. Important design limitations of the RAND/
University of California, Los Angeles (UCLA) consen-
sus methodology that was used in this study are the lack
of inclusion of societal costs of health care and the
absence of costs and cost-effectiveness of tests in the
analyses (10). These recommendations are not meant to
be prescriptive and are based on currently available
evidence. The recommendations cannot and should not
be substituted for individualized direct assessment of the
patient, coupled with clinical decision-making by a com-
petent health care practitioner. Importantly, the recom-
mendations presented here are not intended to limit or
deny third party payor coverage of health care costs for
groups or individual patients.
MATERIALS AND METHODS
Project design and development of recommendations
and grading of evidence. The RAND/UCLA consensus meth-
odology, which was developed in the 1980s, incorporates both
Delphi and nominal group methods and was successfully used
to develop other guidelines and recommendations commis-
sioned by the American College of Rheumatology (11–14).
The purpose of this methodology is to reach a consensus
among experts, with an understanding that published literature
may not be adequate to provide sufficient evidence for day-to-
day clinical decision-making. The RAND/UCLA method re-
quires 2 groups of experts: a core expert panel that provides
input into case scenario development and preparation of a
scientific evidence report, and a task force panel that votes on
these case scenarios. A systematic review of pertinent litera-
ture was performed that focused on PAH (15) and excluded
articles that assessed World Health Organization (WHO)
groups 2 and 3 (detailed in Supplementary Appendix 1,
available on the Arthritis & Rheumatism web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.38172/abstract), and
the resulting scientific evidence report was given to the task
force panel in conjunction with clinical scenarios representing
a broad scope of disease. The scenarios illustrated multiple
questions of interest and alternative options.
The core expert panel consisted of 2 experts on CTD-
associated PAH (1 rheumatologist and 1 cardiologist), 2
trainees in rheumatology who conducted the systematic review,
and 1 expert on the RAND/UCLA methodology. The task
force panel consisted of a diverse group of experts: 3 rheuma-
tologists, 1 internist, 4 pulmonologists, and 2 cardiologists, all
with extensive experience and publications in the field of
pulmonary vascular disease. There were 2 rounds of ratings.
First, using the Delphi process, members of the task force
panel anonymously ranked each of the potential elements
of the recommendations on a risk–benefit basis ranging from
1 to 9 on a Likert scale. A vote of 1–3 was weighed as
inappropriate—the risks clearly outweighed the benefits. A
vote of 4–6 was considered uncertain—the risk/benefit ratio
was uncertain. A vote of 7–9 was weighed as appropriate—the
benefits clearly outweighed the risks. Votes on case scenarios
were translated into recommendations if the median voting
score was between 7 and 9 (“appropriate”) and if there was no
significant disagreement, defined as no more than one-third of
the votes between 1 and 3 (“inappropriate”) for the scenario.
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For the second round of voting, the task force panel
and the core expert panel convened for a face-to-face meeting
to review the results of first-round voting. All task force panel
members attended the meeting. During this meeting, a mod-
erator experienced in the RAND/UCLA methodology (JF) led
a discussion of the first-round voting results. Where areas of
discrepancy were identified, discussion between members of
the task force panel (and the core expert panel when requested
by the task force panel) was used to clarify discrepant view-
points and reach consensus where possible.
A priori, “appropriate” results (median vote 7–9, with-
out significant disagreement [defined as no more than one-
third of the votes between 1 and 3]) were included as recom-
mendations. During the face-to-face task force panel meeting,
some case scenarios were clarified for content based on task
force panel discussion and voted on again by the task force
panel as necessary.
To evaluate the risk of bias and quality of our studies,
we used the Quality Assessment of Diagnostic Accuracy
Studies (QUADAS) evaluation tool (16,17). The QUADAS
tool assesses the risk of bias in 4 domains, including patient
selection, index test, reference standard, and flow and timing.
Studies graded as low risk in all domains have the highest
quality. Based on the results of the QUADAS evaluation, we
also assessed the quality of evidence as proposed by the
Grading of Recommendations Assessment, Development and
Evaluation (GRADE) Working Group (18,19). Briefly, a
recommendation is assessed as high quality if further research
is unlikely to change the recommendations, moderate quality if
further research is likely to affect our recommendations and
may result in change, low quality if further research is very
likely to affect our recommendations and likely result in
change, and very low quality if recommendations are uncer-
tain. The GRADE quality rating reflects the published evi-
dence available to support a recommendation.
Definitions for the case scenarios. For these recom-
mendations, screening is defined as “the presumptive identifi-
cation of unrecognized disease by the application of tests,
examinations, or other procedures which can be applied rap-
idly” (20). This assumes that a patient has no symptoms
attributable to pulmonary hypertension (PH). Detection is
defined as the identification of patients with signs and/or
symptoms attributable to PH. The definition of a particular
CTD was based on the criteria published by rheumatology
associations such as the American College of Rheumatology
(21) or different authors (22–25). However, the panel acknowl-
edged that diagnosis of a CTD is based on the physician’s
evaluation of the patient, as classification and diagnostic
criteria are not synonymous. In addition, it was agreed that
patients could have more than 1 CTD if they met the published
criteria. A glossary is provided for the terminology used in
these recommendations (see Supplementary Appendix 2,
available on the Arthritis & Rheumatism web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.38172/abstract).
RESULTS
General recommendations (Table 1). The task
force panel voted that every patient with SSc should be
screened for PAH due to its high prevalence in SSc
(moderate quality evidence) (1,2,26). In addition, pa-
tients with MCTD or other CTDs with prominent sclero-
derma features (such as sclerodactyly, nailfold capillary
abnormalities, or scleroderma-specific autoantibodies),
referred to hereafter as scleroderma spectrum disorders,
should be screened for PAH due to high risk of PAH in
these patients (very low quality evidence) (8,27). Screen-
ing was not recommended for patients with MCTD or
CTDs without features of scleroderma, as the preva-
lence of PAH is either low or poorly defined in these
patient populations (low-to-moderate quality evidence)
(4,8,28). Right-sided heart catheterization (RHC) was
voted as mandatory for the diagnosis of PAH in all
patients (high quality evidence). It was emphasized that
Table 1. General recommendations, initial screening evaluation, and
frequency of noninvasive tests for early detection of CTD-associated
PAH*
General recommendations
All patients with SSc should be screened for PAH (Moderate)
Patients with MCTD or other CTDs with scleroderma features
(scleroderma spectrum disorders) should be screened in a
similar manner to patients with SSc (Very low)
Screening is not recommended for asymptomatic patients with
MCTD or other CTDs (including SLE, rheumatoid arthritis,
inflammatory myositis, Sjögren’s syndrome) without features of
scleroderma (Low to moderate)
For unexplained signs and symptoms of PH in patients with
MCTD, SLE, or other CTDs without scleroderma features, one
may consider the diagnostic algorithm evaluation for PH
(Moderate)
All patients with SSc and scleroderma spectrum disorders with a
positive results on a noninvasive screen (see below) should be
referred for RHC (High)
RHC is mandatory for diagnosis of PAH (High)
Acute vasodilator testing is not required as part of the evaluation
of PAH in patients with SSc, scleroderma spectrum disorders,
or other CTDs (Moderate to high)
Initial screening evaluation
PFTs with DLCO (High)
Transthoracic echocardiogram (High)
NT-proBNP (Moderate)
DETECT algorithm if DLCO 60% predicted and disease
duration 3 years (Moderate)
Frequency of noninvasive tests
Transthoracic echocardiogram annually as a screening test (Low)
Transthoracic echocardiogram if new signs or symptoms develop
(High)
PFTs with DLCO annually as a screening test (Low)
PFTs with DLCO if new signs or symptoms develop (Low)
NT-proBNP if new signs or symptoms develop (Low)
* The quality of evidence, which was assessed according to the Grading
of Recommendations Assessment, Development and Evaluation
Working Group, is shown in parentheses at the end of each statement.
CTD  connective tissue disease; PAH  pulmonary arterial hyper-
tension; SSc  systemic sclerosis; MCTD  mixed connective tissue
disease; SLE  systemic lupus erythematosus; PH  pulmonary
hypertension; RHC  right-sided heart catheterization; PFTs 
pulmonary function tests; DLCO  diffusing capacity for carbon
monoxide; NT-proBNP  N-terminal pro–brain natriuretic peptide;
DETECT  DETECTion of PAH in SSc.
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PAH be defined by a mean pulmonary artery pressure
(PAP) of 25 mm Hg with a pulmonary capillary wedge
pressure of 15 mm Hg (28) on resting RHC. Addi-
tional diagnostic criteria may include a pulmonary vas-
cular resistance of 3 Wood units (7) in the presence of
either normal or reduced cardiac output. In all cases,
chronic thromboembolic PH (WHO group 4) must be
excluded by ventilation/perfusion lung scanning, helical
computed tomography, or conventional pulmonary an-
giography (7). Ventilation/perfusion lung scanning is the
preferred diagnostic test (29) but may be suboptimal
with concomitant lung fibrosis. Patients with SSc and
scleroderma spectrum disorders with positive findings
on a noninvasive screen (as presented in the next
section) should be referred for RHC (high quality
evidence).
Initial evaluation in patients with SSc and
scleroderma spectrum disorders. It was recommended
that screening pulmonary function tests (PFTs; spirom-
etry with lung volumes) with single-breath diffusing
capacity for carbon monoxide (DLCO) (high quality
evidence), transthoracic echocardiogram (high quality
evidence), and measurement of N-terminal pro–brain
natriuretic peptide (NT-proBNP) (moderate quality ev-
idence) be performed in all patients with SSc and
scleroderma spectrum disorders. The panel also en-
dorsed the use of the DETECT (DETECTion of PAH in
SSc) algorithm in these patients if their DLCO was60%
predicted and if the duration of their SSc was 3 years
from the time of their first non–Raynaud’s phenomenon
symptom (moderate quality evidence) (30).
Frequency of noninvasive tests. The task force
panel recommended that transthoracic echocardiogram
and PFTs should be performed annually on all patients
with SSc (low quality evidence) and scleroderma spec-
trum disorders (very low quality evidence). At the onset
of any new signs or symptoms of PH, transthoracic
echocardiogram (high quality evidence), PFTs (low
quality evidence), and measurement of NT-proBNP
(low quality evidence) should be performed.
Referral for RHC (Table 2). The task force panel
recommended that acute vasodilator testing during
RHC not be required as part of the evaluation of PAH,
given the negligible proportion of patients in this popu-
lation with both a positive vasodilator test result (de-
fined as a reduction in mPAP by at least 10 mm Hg to an
mPAP of 40 mm Hg in the setting of a normal cardiac
output) and a long-term response to calcium-channel
blockers (moderate to high quality evidence) (8,31).
However, although this was not voted upon, it was
discussed that there may be other reasons that individual
physicians may wish to perform vasodilator challenge in
these patients (e.g., insurance requirements).
The task force panel voted that patients with SSc
and scleroderma spectrum disorders and signs and/or
symptoms of PH who had a tricuspid regurgitation (TR)
jet velocity of 2.5–2.8 meters/second (corresponding to a
transtricuspid gradient of 25–31 mm Hg) should be
referred for RHC (high quality evidence). In addition,
all patients (with or without signs and/or symptoms of
PH) with a TR jet velocity of 2.8 meters/second
(corresponding to a transtricuspid gradient of 31 mm
Hg) should be referred for RHC (high quality evidence).
Moreover, all patients with right atrial or right ventric-
ular enlargement (right atrium major dimension 53
mm and right ventricle midcavity dimension 35 mm),
irrespective of TR jet velocity (including unmeasurable
or 2.5 meters/second), should be referred for RHC
(high quality evidence). RHC was recommended for
patients with signs or symptoms of PH and a forced vital
capacity % predicted to DLCO % predicted ratio of1.6
and/or a DLCO of 60% predicted, where a transtho-
Table 2. Recommendations for RHC for SSc and scleroderma spec-
trum disorders*
Signs or
symptoms
required for
RHC†
Quality of
evidence
Transthoracic echocardiogram
TR jet velocity
2.5–2.8 meters/second Yes High
2.8 meters/second No High
Right atrial or right ventricular
enlargement (right atrium major
dimension 53 mm and right
ventricle midcavity dimension
35 mm), irrespective of TR jet
velocity
No High
PFTs
FVC:DLCO ratio 1.6 and/or DLCO
60% predicted‡
Yes High
FVC:DLCO ratio 1.6 and/or DLCO
60% predicted and NT-proBNP
2 times upper limit of normal‡
No High
Composite measure
Meets DETECT algorithm in patients
with DLCO 60% predicted and
disease duration 3 years‡
No Moderate
* TR tricuspid regurgitation; FVC forced vital capacity (see Table
1 for other definitions).
† Signs include loud pulmonic sound and peripheral edema. Symptoms
include dyspnea on rest or exercise, fatigue, presyncope/syncope, chest
pain, palpitations, dizziness, and lightheadedness.
‡ Where a transthoracic echocardiogram did not reveal overt systolic
dysfunction, greater than grade I diastolic dysfunction, greater than
mild mitral or aortic valve disease, or evidence of PH (as defined in the
transthoracic echocardiogram section).
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racic echocardiogram did not reveal overt systolic dys-
function, greater than grade I diastolic dysfunction,
greater than mild mitral or aortic valve disease, or
evidence of PH (high quality evidence). Other scenarios
are shown in Table 2. In MCTD or other CTDs without
scleroderma features, the presence of unexplained signs
and symptoms of PH should lead to consideration of the
published diagnostic algorithm for PH (low quality
evidence).
Scenarios were discussed regarding the need for
serial screening in patients with CTDs with normal RHC
findings who might subsequently meet the above recom-
mended indications for RHC during followup visits;
however, firm recommendations could not be reached
due to lack of published data. However, the panelists
emphasized the need for clinical judgment on a patient-
by-patient basis, along with further research in this area.
The panelists did not provide recommendations on
borderline mean PAP (21–24 mm Hg) or exercise-
induced PH due to lack of long-term outcomes data and
variability in exercise testing (32,33). The panelists did
agree that this is an important research agenda for
patients at high risk of PAH, such as those with SSc and
scleroderma spectrum disorders. In addition, there was
no consensus on the definition of moderate-to-severe
interstitial lung disease (ILD) to classify a patient in
WHO group 3. The panelists believed that further
research is needed to define this and that current
published definitions should be used for recommenda-
tions concerning ILD.
DISCUSSION
We present the first evidence- and consensus-
based recommendations for screening and early detec-
tion of CTD-associated PAH. The recommendations are
written for health care providers (such as rheumatolo-
gists and primary care physicians) who evaluate and
treat patients with CTDs. The recommendations are
presented to encourage screening, and therefore early
diagnosis, of CTD-associated PAH. Screening is defined
as the systematic testing of asymptomatic individuals for
preclinical disease (20). The purpose of screening and
early detection is to identify those with asymptomatic/
preclinical disease and those with mild symptoms in
order to prevent or delay progression of disease through
early management. Screening programs play an impor-
tant part in the detection of PAH in certain “at-risk”
populations and may enable patients with PAH to be
identified at an earlier stage than in routine clinical
practice. This is particularly important in patients with
CTDs, who may be relatively sedentary and may there-
fore not develop symptoms until their disease is quite
advanced. However, screening tests are not meant to be
diagnostic, and appropriate tests (RHC in the case of
PAH) should be performed to make a diagnosis.
The prevalence of PAH is 8–12% in patients with
SSc, and PAH is responsible for almost 30% of SSc-
related deaths (34). In a single-center study of patients
with MCTD, 64% of mortality was attributed to PAH at
a mean followup of 15 years (3). Other CTDs have also
been shown to be associated with PAH (4,5,35). The
value of screening for PAH in patients with SSc has been
highlighted by the recent work of Humbert and col-
leagues (2). In that prospective study, SSc patients
whose PAH was identified in an early detection program
(n  16) were compared with SSc patients whose PAH
was diagnosed during routine clinical practice (n  16).
At the time of PAH diagnosis, patients whose PAH was
identified in an early detection program had less ad-
vanced pulmonary vascular disease than patients whose
PAH was diagnosed during routine clinical practice (36).
At diagnosis, 6% of patients whose PAH was detected by
screening were in New York Heart Association (NYHA)
functional class I (37) and 44% were in NYHA func-
tional class II. These results contrast sharply with those
for the patients whose PAH was diagnosed in routine
practice, the majority of whom were already in NYHA
functional class III or IV at the time of diagnosis (69%
and 18.5%, respectively). Patients in the screening pro-
gram had significantly greater survival rates at 8 years
than patients whose PAH was identified in routine
clinical practice (64% versus 17%; P 0.004). The small
sample size and effect of lead-time bias may have led to
this effect, which needs to be confirmed in a larger study.
The resulting recommendations of the task force
panel take into account recommendations from profes-
sional societies as well as systematic review of reported
studies (15). The European Society of Cardiology/
European Respiratory Society guidelines (8) recom-
mend annual transthoracic echocardiogram screening of
symptomatic SSc patients, and annual screening of
asymptomatic SSc patients “may be considered” (7).
Similar to our recommendations, the American College
of Cardiology Foundation Task Force on Expert Con-
sensus Documents and the American Heart Association
recommend yearly transthoracic echocardiogram and
referral for RHC if transthoracic echocardiogram shows
elevated PAP (high right ventricular systolic pressure
[RVSP] estimates or enlargement of the right heart
chambers) (7). The American College of Chest Physi-
cians recommends transthoracic echocardiogram for
clinical suspicion of PAH in order to evaluate for
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elevated estimated RVSP and right atrial and ventricular
enlargement (9).
However, none of the published recommenda-
tions includes use of other noninvasive screening tests
(such as PFTs) or measurement of serum biomarkers
(such as NT-proBNP) that have been shown to be
associated with PAH in SSc patients (30,38–41). For
example, the Itine´rAIR-Scle´rodermie PAH detection
study screened 195 patients with symptoms consistent
with SSc-associated PAH. Gas transfer analyses deter-
mined that DLCO was 60% predicted in 162 patients,
of whom 13 (8%) had PAH (42). Also, in a recent
prospective cohort, the presence of elevated NT-
proBNP (97th percentile of normal) and a DLCO/
alveolar volume 70% predicted was associated with a
hazard ratio of 47.2 for developing PAH at 36 months
(40). Finally, measurement of NT-proBNP level was
found to be a good screening test in 2 large SSc cohorts
(39,41).
A combination of transthoracic echocardiogram
and PFTs might be used to enrich the screening popu-
lation of patients with SSc (30,40,43,44); a recent report
proposed a representative algorithm of noninvasive tests
for screening/early detection of SSc-associated PAH
(30). In the DETECT study, which included patients
with SSc and scleroderma spectrum disorders, an en-
riched cohort of 466 patients (adults with 3 years’
disease duration from the first non–Raynaud’s phenom-
enon symptom, and a DLCO 60% predicted) under-
went noninvasive testing and RHC. Of those 466 pa-
tients, 87 (19%) had RHC-confirmed PAH (30).
However, the DETECT study did not provide recom-
mendations regarding patients with a DLCO 60%
predicted or patients in whom the results of DETECT
screening are negative, and its findings need to be
validated in another cohort.
The task force panel recommended that patients
with signs and/or symptoms of PH who had a TR jet
velocity of 2.5–2.8 meters/second should be referred for
RHC, and that all patients (with or without signs and/or
symptoms of PH) with a TR jet velocity of 2.8 meters/
second should be referred for RHC. This is supported by
large cohort studies in which a TR jet velocity of
2.73–3.0 meters/second without signs or symptoms of
PH or2.5 meters/second with signs or symptoms of PH
was used for referral for RHC (42,45–48). The RVSP on
transthoracic echocardiogram can be estimated by the
modified Bernoulli equation: RVSP  4(TR jet veloc-
ity)2  right atrial pressure. Guidelines have been
established for the estimation of right atrial pressure
based on inferior vena cava diameter and respiratory
variation, but these are most accurate at the extremes
(49). However, in practice, there is variation from one
laboratory to another and even among echocardiogra-
phers in the same laboratory as to how echocardiogra-
phers add the estimated right atrial pressure. TR jet
velocities of 2.5 meters/second, 2.8 meters/second, and
3.0 meters/second correspond to transtricuspid gradi-
ents of 25 mm Hg, 31 mm Hg, and 36 mm Hg,
respectively. Thus, the variation of 5–10 mm Hg for the
estimated right atrial pressure has the potential to alter
the decision-making process regarding an individual
patient.
To reduce this variability, we chose to base cri-
teria on the TR jet velocity rather than on the estimated
RVSP. This approach, while methodologically sound,
may not be applicable in broad clinical practice, as many
echocardiography laboratories report the estimated
RVSP as opposed to the TR jet velocity. For practical
purposes, a TR jet velocity of 2.5 meters/second corre-
sponds to an estimated RVSP of 30–35 mm Hg, assum-
ing a right atrial pressure of 5–10 mm Hg.
The task force panel recommended performing
noninvasive transthoracic echocardiogram and PFTs an-
nually in patients with SSc and scleroderma spectrum
disorders. Although there is a lack of evidence regarding
the frequency of tests, a high incidence of PAH is
observed in these patients. In addition, an annual trans-
thoracic echocardiogram is consistent with some of the
other recommendations in SSc (7,8). The societal eco-
nomic costs of such recommendations are unclear. Early
treatment may improve outcomes (acknowledging that
knowledge gaps still exist in SSc-associated PAH). Car-
ing for patients with milder disease could lower medical
costs. However, medical costs to society could theoreti-
cally be increased by expensive medical therapies for
PAH or through extended courses of care (because of
greater longevity). The costs of screening and the po-
tential impact of the results are complicated and are
beyond the scope of this project. The RAND/UCLA
method excludes cost-efficacy considerations, as this
would require a separate literature data set for decision-
making. Further research is needed in this area.
Our study has many strengths. We used an estab-
lished consensus methodology (50) that has a foundation
in rheumatology and has been used in recent guidelines
supported by the American College of Rheumatology
(11–13,51). In addition, we assessed the quality of the
studies using the QUADAS evaluation tool. A majority
(16 of 22) of our studies were cohort studies and were
rated as having a high quality of evidence (low risk of
bias or applicability concerns) on the QUADAS evalu-
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ation scale (15). We followed the GRADE methodology
to assign quality to the recommendations. The majority
of the recommendations are of moderate-to-high qual-
ity. Also, we had a diverse group of experts (cardiolo-
gists, internist, pulmonologists, and rheumatologists)
who participated as the panelists.
Limitations of the recommendations include the
RAND/UCLA methodology used for this project, as it
did not allow us to address the important societal
implications of screening or early detection of PAH. For
example, the costs of proposed screening tests are not
considered in these recommendations. This is true of
other recommendations published in medicine using this
methodology. Also, treatment was not evaluated as part
of these recommendations.
In conclusion, we provide consensus-based and
evidence-driven recommendations for screening and
early detection of CTD-associated PAH. It is our hope
that these recommendations will lead to early detection
of CTD-associated PAH and ultimately improve patient
outcomes. As with any recommendations, these should
be updated as more evidence becomes available.
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